SMARTER INVESTMENT IN THE RESEARCH LONG GAME Government support for health and medical researchers and innovators needing investment cycle review
With
Nadia Levin, CEO
Research Australia
OP-ED SEGMENT
Filmed in Sydney | April 2026
In this Op-Ed, Nadia Levin, CEO of Research Australia, spoke with the Australian Health Journal about the need for smarter and more strategic investment in Australia’s health and medical research sector.
Levin argued that Australia’s approach to health and medical research has been shaped too heavily by short-term political cycles rather than a long-term national vision. She emphasised that meaningful progress in science, innovation, and healthcare requires sustained investment over many years.
According to Levin, health and medical research should not be viewed simply as a social good, but as a major driver of economic growth, productivity, and national resilience. She highlighted that every preventable hospital admission, faster diagnosis, or locally developed medical product contributes to economic performance.
Research Australia estimates that for every dollar invested in health and medical research, the Australian economy receives around four dollars in return.
Levin pointed to Australia’s past achievements, including the development of IVF, the cochlear implant, the HPV vaccine, and ultrasound imaging, as examples of how research can improve lives while creating industries and export opportunities.
A major focus in the need to strengthen the entire research pipeline, from early-stage discovery through to clinical translation, commercialisation, and integration into healthcare systems. Research Australia in a media release March 2026, noted that while the Medical Research Future Fund was created to distribute around $1 billion annually, it is currently providing only about $650 million each year despite holding approximately $24.5 billion.
Levin referenced costings from the Parliamentary Budget Office (PBO), commissioned by Dr Monique Ryan MP, showing the fund could distribute up to $1.4 billion annually without reducing its capital base, arguing that the money, demand, and need already exist, but stronger government commitment is required.
Source: Adapted from Research Australia media release March 2026
-
Growing impact of blood cancer on women
According to the Leukaemia Foundation, blood cancer is one of the most urgent and under-recognised women’s health issues in Australia, with three times more Australian women diagnosed with blood cancer than ovarian and cervical cancer combined (Source: AIHW, Cancer Data in Australia, 2024).
Blood cancer has also emerged as the second most common cancer diagnosed in Australian women overall – behind only breast cancer – and the leading cancer amongst girls and women under the age of 30 (Source: AIHW, Cancer Data in Australia, 2024).
-
The Northernmost Pharmacist in Australia
Carli Berrill is a Co-Owner and Pharmacist of two pharmacies in Far North Queensland, including one on Thursday Island in Torres Strait, which is the most northern pharmacy in Australia.
Her role with the Thursday Island Pharmacy is to provide essential health and pharmacy services to 15 communities, including remote islands south of Papua New Guinea. The role for the community is the important ‘constant’ in being a trusted and familiar healthcare professional.
-
Australian Teletrial Program reaches significant milestones in trials and participants
Launched in 2022, the Australian Teletrial Program is an initiative designed to improve access to clinical trials for people living in regional and remote areas of Australia. It uses telemedicine and digital technologies to enable patients to participate in clinical trials without needing to travel long distances to major metropolitan centres, which can often be a barrier to participation for those in rural and isolated locations.
Recently Australian Health Journal met with Kaye Hewson, Director, Australian Teletrials Program, who spoke about the program’s recent achievements.
